Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura

Clin Mol Hepatol. 2022;28(3):575-579. Published online April 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0047

View: 3248 Download: 202 Web of Science: 6 Crossref: 6

5

Well differentiated hepatocellular carcinoma: Pathological diagnosis of needle biopsied Liver tissue

Jae Yeon Seok , Young Nyun Park

Clin Mol Hepatol. 2009;15(1):96-100. Published online March 31, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.1.96

View: 3723 Download: 26

1

PIVKA-II as a Serological Marker of Hepatocellular Carcinoma

Sook-Hyang Jeong

Clin Mol Hepatol. 2006;12(3):315-317. Published online January 1, 2000

View: 2526 Download: 23

3

Clinical Efficacy of Serum PIVKA-2 in the Diagnosis and Follow up after Treatment of Hepatocellular Carcinoma

Young Joon Yoon, M.D., Kwang-Hyub Han, M.D., Chul Kim, M.D., Chae Yoon Chon, M.D., Young Myoung Moon, M.D., Chang Hoon Han, M.D., Hye Jin Choi, M.D., Yong Soo Kim, M.D., Jae Yong Han, M.D. and Hyon Suk Kim, M.D.†

Clin Mol Hepatol. 2002;8(4):465-471. Published online January 1, 1970

View: 3092 Download: 25

Clinical Implication of Automatically Analysed AFP - L3 and PIVKA - 2 in the Diagnosis of Hepatocellular Carcinoma

Cheol Kim, M.D.*, Kwang Hyub Han, M.D.*, Yong Han Paik, M.D.*, Kun Hoon Song, M.D.*, Jae Yeon Jeong, M.D.*, Jeong Youp Park, M.D.*, Young Soo Park, M.D.*, Hyun Woong Lee, M.D.*, Tae Joo Jeon, M.D.*, Jae Yong Han, M.D.*, Kwan Sik Lee, M.D.*, Chae Yoon Chon, M.D.*, Young Myoung Moon, M.D.*, Kyoung Rhyul Lee, M.D.† , and Hyon Suk Kim, M.D.†

Clin Mol Hepatol. 2001;7(4):467-474. Published online January 1, 1970

View: 2749 Download: 25

Clinical Usefulness of PIVKA-II and Lens Culinaris Agglutinin-A Reactive Alpha-fetoprotein(AFP-L3) for the Diagnosis of Hepatocellular Carcinoma

B.H. Byun, Y.M. Park, S.H. Bae, J.Y. Choi, K.Y. Sung, S.H. Cho, N.I. Hahn, J.M. Yang, S.O. Choi, S.B. Cha, K.W. Chung, H.S. Sun, D.H. Park, B.S. Kim

Clin Mol Hepatol. 2000;6(2):205-214. Published online January 1, 2000

View: 2551 Download: 36

1 |

Viewed By 5831	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5145	MAFLD: How is it different from NAFLD?
Viewed By 4876	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3972	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 3962	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 136	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 104	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 82	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 71	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 61	MAFLD: How is it different from NAFLD?

Search